Advertisement

The U.S. Food and Drug Administration has granted fast track review status to Cambridge biotech Pervasis Therapeutics Inc. for Vascugel, its lead drug program, a prevention treatment of kidney dialysis access failure in patients with end stage renal disease.

Vascugel was tested in two Phase 2 clinical trials on patients with end stage renal disease, and it returned positive safety and efficacy results. According to a news release from Pervasis, the cell-based treatment is intended to “regulate the body’s healing response following surgical interventions.”

SOURCE

Advertisement
Advertisement